Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Matthew J. Ellis(Washington University in St. Louis), J.F.R. Robertson(University of Nottingham), Marek Jasiówka(Hospital Arnau de Vilanova), David Feltl(University Hospital Ostrava), Nicola Hewson(Hospital Arnau de Vilanova), Yuri Rukazenkov(Chinese University of Hong Kong), John Dewar(University Hospital Ostrava), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU)
Cited by 239
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k